Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:59:27 EDT Thu 02 May 2024
Enter Symbol
or Name
USA
CA



News for U:BGNE from 2023-05-03 to 2024-05-02 - 40 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-26 10:34U:BGNENews ReleaseBeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
2024-04-24 16:01U:BGNENews ReleaseGlobal Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
2024-04-23 06:00U:BGNENews ReleaseBeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
2024-03-14 16:28U:BGNENews ReleaseBeiGene Receives FDA Approval for TEVIMBRA(TM) for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
2024-03-13 08:00U:BGNENews ReleaseFirst Doses of BRUKINSA(TM) provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
2024-03-07 17:19U:BGNENews ReleaseBeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
2024-03-06 06:00U:BGNENews ReleaseBeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
2024-02-29 10:00U:BGNENews ReleaseBeiGene Announces New Efficacy Analysis Comparing BRUKINSA(TM) vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
2024-02-28 08:05U:BGNENews ReleaseBeiGene to Present at Upcoming Investor Conferences
2024-02-27 06:00U:BGNENews ReleaseBeiGene's Biologics License Application for TEVIMBRA(TM) (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
2024-02-26 06:00U:BGNENews ReleaseBeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
2024-02-26 05:00U:BGNENews ReleaseBeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
2024-01-23 06:00U:BGNENews ReleaseBeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
2023-12-22 06:00U:BGNENews ReleaseFDA Approves Label Update for BRUKINSA ‚ ® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
2023-12-21 06:01U:BGNENews ReleaseBeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-29 16:01U:BGNENews ReleaseBeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023
2023-11-28 06:00U:BGNENews ReleaseBeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
2023-11-21 06:00U:BGNENews ReleaseBeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
2023-11-17 06:00U:BGNENews ReleaseBeiGene Receives European Commission Approval for BRUKINSA ‚ ® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
2023-11-09 16:01U:BGNENews ReleaseBeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
2023-11-08 06:00U:BGNENews ReleaseBeiGene to Present at the Jefferies London Healthcare Conference
2023-10-20 06:00U:BGNENews ReleaseBRUKINSA ‚ ® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
2023-10-17 16:01U:BGNENews ReleaseBeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)
2023-10-17 16:01U:BGNENews ReleaseBeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
2023-10-16 06:00U:BGNENews ReleaseBeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeline Assets
2023-10-13 11:51U:BGNENews ReleaseBeiGene Receives Positive CHMP Opinion for BRUKINSA ‚ ® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma
2023-09-19 06:15U:BGNENews ReleaseBeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA ‚ ®
2023-09-19 06:00U:BGNENews ReleaseBeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA ‚ ® (tislelizumab)
2023-08-31 07:00U:BGNENews ReleaseBeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-02 06:00U:BGNENews ReleaseBeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
2023-07-21 07:50U:BGNENews ReleaseBeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
2023-07-10 07:00U:BGNENews ReleaseBeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
2023-07-07 07:00U:BGNENews ReleaseBeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023
2023-06-15 08:37U:BGNENews ReleaseBeiGene to Vigorously Defend Patent Infringement Allegations by Pharmacyclics
2023-06-09 03:01U:BGNENews ReleaseBeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress
2023-05-30 07:00U:BGNENews ReleaseBRUKINSA ‚ ® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
2023-05-25 17:05U:BGNENews ReleaseBeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio
2023-05-24 07:00U:BGNENews ReleaseBeiGene to Present at Upcoming Investor Conferences
2023-05-17 07:00U:BGNENews ReleaseThe Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA ‚ ® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
2023-05-06 08:00U:BGNENews ReleaseBeiGene Receives New Approvals for BRUKINSA ‚ ® (zanubrutinib) in China